Kendall Law Group Investigates Allergan, Inc. for Shareholders

DALLAS--(EON: Enhanced Online News)--Kendall Law Group a national securities firm led by a former federal judge with attorneys that include a former U.S. Attorney, is investigating Allergan, Inc. (NYSE: AGN) for shareholders. The investigation concerns potential breaches of fiduciary duties by the board of directors and other company executives in connection to alleged violations of the False Claims Act. Concerned Allergan shareholders should contact the Kendall Law Group at 877-744-3728 or by email at [e-mail].

On September 2, 2010, Allergen agreed to pay $600 million to settle charges that it illegally promoted and sold Botox through 2005 for unapproved uses. Allergan agreed to plead guilty to one criminal misdemeanor charge, to pay $375 million to the government for misbranding Botox, and to pay $225 million to resolve civil charges that it caused false claims to be submitted to Medicare, Medicaid and other government health programs. In addition, Allergan has entered into a five year corporate integrity agreement under which the company will be required to publish information about payments made to doctors.

Kendall Law Group has the credentials and experience to pursue any type of complex securities litigation in the nation. The firm helps shareholders exercise their power to protect their investments when companies break the law. If you are an Allergan shareholder, you are encouraged to contact the Kendall Law Group to learn more about your rights.